Lyell Immunopharma (LYEL) Change in Accured Expenses (2020 - 2026)
Lyell Immunopharma recorded quarterly Change in Accured Expenses of -$3.6 million in Q1 2026, down 172.74% quarter-over-quarter from $4.9 million in Q4 2025, and up 63.56% year-over-year from -$2.2 million in Q1 2025.
Lyell Immunopharma's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 63.56% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$1.4 million (up 80.88% YoY), while the FY2025 annual figure was -$7.6 million, down 511.36% from the prior year.
- Change in Accured Expenses came in at -$3.6 million for Q1 2026 at Lyell Immunopharma, down from $4.9 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $5.4 million in Q4 2022 to a low of -$9.8 million in Q1 2025.
- A 5-year average of -$802411.8 and a median of -$766000.0 in 2022 frame the typical range for Change in Accured Expenses.
- On a YoY basis, Change in Accured Expenses climbed as much as 491.07% in 2025 and fell as far as 745.35% in 2025.
- Lyell Immunopharma's Change in Accured Expenses stood at $5.4 million in 2022, then slumped by 132.37% to -$1.7 million in 2023, then grew by 27.89% to -$1.3 million in 2024, then soared by 491.07% to $4.9 million in 2025, then sank by 172.74% to -$3.6 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.6 million, $4.9 million, and $572000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | -3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.57 Mn |
| Mar 31, 2026 | -3.57 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 572,000.00 |
| Sep 30, 2025 | 572,000.00 |
| Jun 30, 2025 | -3.33 Mn |
| Jun 30, 2025 | -3.33 Mn |
| Mar 31, 2025 | -9.79 Mn |
| Mar 31, 2025 | -9.79 Mn |
| Dec 31, 2024 | -1.25 Mn |
| Dec 31, 2024 | -1.25 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 516,000.00 |
| Jun 30, 2024 | 516,000.00 |
| Mar 31, 2024 | -3.61 Mn |
| Mar 31, 2024 | -3.61 Mn |
| Dec 31, 2023 | -1.74 Mn |
| Dec 31, 2023 | -1.74 Mn |
| Sep 30, 2023 | 4.61 Mn |
| Sep 30, 2023 | 4.61 Mn |
| Jun 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 2.27 Mn |
| Mar 31, 2023 | -5.86 Mn |
| Mar 31, 2023 | -5.86 Mn |
| Dec 31, 2022 | 5.37 Mn |
| Dec 31, 2022 | 5.37 Mn |
| Sep 30, 2022 | 1.32 Mn |
| Sep 30, 2022 | 1.32 Mn |
| Jun 30, 2022 | -766,000.00 |
| Jun 30, 2022 | -766,000.00 |
| Mar 31, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.39 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | 1.94 Mn |
| Sep 30, 2021 | 1.94 Mn |
| Jun 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 3.08 Mn |
| Mar 31, 2021 | -4.70 Mn |
| Mar 31, 2021 | -4.70 Mn |
| Dec 31, 2020 | 1.91 Mn |
| Dec 31, 2020 | 1.91 Mn |
| Sep 30, 2020 | 848,000.00 |
| Sep 30, 2020 | 848,000.00 |